BST:DYXA

Stock Analysis Report

Executive Summary

Dynatronics Corporation designs, manufactures, and sells orthopedics, physical therapy, rehabilitation, pain management, and athletic training products in the United States and internationally.


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Dynatronics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DYXA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.6%

DYXA

0.9%

DE Medical Equipment

-0.6%

DE Market


1 Year Return

-56.8%

DYXA

6.5%

DE Medical Equipment

-20.9%

DE Market

Return vs Industry: DYXA underperformed the German Medical Equipment industry which returned 6.5% over the past year.

Return vs Market: DYXA underperformed the German Market which returned -20.9% over the past year.


Shareholder returns

DYXAIndustryMarket
7 Day-12.6%0.9%-0.6%
30 Day-71.7%-4.9%-16.6%
90 Day-9.9%-12.0%-26.0%
1 Year-56.8%-56.8%8.1%6.5%-18.6%-20.9%
3 Year-70.9%-70.9%101.2%95.8%-19.0%-25.8%
5 Yearn/a216.5%201.9%-21.1%-31.8%

Price Volatility Vs. Market

How volatile is Dynatronics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dynatronics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DYXA (€0.73) is trading below our estimate of fair value (€20.79)

Significantly Below Fair Value: DYXA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DYXA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: DYXA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DYXA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DYXA is good value based on its PB Ratio (0.7x) compared to the DE Medical Equipment industry average (5x).


Next Steps

Future Growth

How is Dynatronics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

66.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DYXA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DYXA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DYXA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DYXA's revenue is expected to decline over the next 3 years (-0.6% per year).

High Growth Revenue: DYXA's revenue is forecast to decline over the next 3 years (-0.6% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DYXA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Dynatronics performed over the past 5 years?

2.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DYXA is currently unprofitable.

Growing Profit Margin: DYXA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DYXA is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare DYXA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DYXA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.9%).


Return on Equity

High ROE: DYXA has a negative Return on Equity (-4%), as it is currently unprofitable.


Next Steps

Financial Health

How is Dynatronics's financial position?


Financial Position Analysis

Short Term Liabilities: DYXA's short term assets ($19.6M) exceed its short term liabilities ($14.4M).

Long Term Liabilities: DYXA's short term assets ($19.6M) exceed its long term liabilities ($6.7M).


Debt to Equity History and Analysis

Debt Level: DYXA's debt to equity ratio (24.1%) is considered satisfactory.

Reducing Debt: DYXA's debt to equity ratio has reduced from 39.8% to 24.1% over the past 5 years.


Balance Sheet

Inventory Level: DYXA has a high level of physical assets or inventory.

Debt Coverage by Assets: DYXA's debt is covered by short term assets (assets are 3.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable DYXA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: DYXA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 28.5% per year.


Next Steps

Dividend

What is Dynatronics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DYXA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DYXA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DYXA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DYXA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DYXA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Brian Baker (52yo)

0.67

Tenure

US$167,896

Compensation

Mr. Brian D. Baker is the Chief Executive Officer, President and Director of Dynatronics Corporation since August 26, 2019 and has served as its Chief Operating Officer since May 29, 2019 until August 26,  ...


CEO Compensation Analysis

Compensation vs Market: Brian's total compensation ($USD167.90K) is below average for companies of similar size in the German market ($USD428.66K).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Brian Baker
President0.67yrUS$167.90k0.38% $29.2k
John Krier
Chief Financial Officer0.083yrno datano data
Jennifer Keeler
General Counsel0.33yrno datano data
Skyler Black
Corporate Controller2.25yrsno datano data
Mark Crockett
Consultantno datano datano data

0.5yrs

Average Tenure

52yo

Average Age

Experienced Management: DYXA's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Brian Baker
President0.67yrUS$167.90k0.38% $29.2k
David Holtz
Independent Director4.33yrsUS$48.60k0.71% $55.2k
Scott Klosterman
Independent Director4.33yrsUS$48.60k0.71% $55.2k
Erin Enright
Independent Chairman of the Board2.17yrsUS$48.60k13.5% $1.1m
R. Ward
Independent Director6.83yrsUS$38.60k0.59% $45.8k
Brian Larkin
Independent Director4.75yrsUS$38.60k1.48% $114.9k

4.3yrs

Average Tenure

55.5yo

Average Age

Experienced Board: DYXA's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.


Top Shareholders

Company Information

Dynatronics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dynatronics Corporation
  • Ticker: DYXA
  • Exchange: BST
  • Founded: 1979
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$8.398m
  • Listing Market Cap: US$7.784m
  • Shares outstanding: 9.95m
  • Website: https://www.dynatronics.com

Number of Employees


Location

  • Dynatronics Corporation
  • 7030 Park Centre Drive
  • Cottonwood Heights
  • Utah
  • 84121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DYNTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 1983
DYXABST (Boerse-Stuttgart)YesCommon StockDEEURNov 1983

Biography

Dynatronics Corporation designs, manufactures, and sells orthopedics, physical therapy, rehabilitation, pain management, and athletic training products in the United States and internationally. The company offers orthopedic soft bracing and support products, which include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also provides power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, recumbent bikes, and other equipment. In addition, the company offers therapeutic modality devices, such as electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. Further, it provides clinical supplies, including exercise bands and tubing, topical analgesics, lotions and gels, orthopedic bracing, paper products, athletic tape, and other products. Dynatronics Corporation distributes its products under the Bird & Cronin, Dynatron Solaris, Hausmann, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, and athletic trainers, sports medicine practitioners, hospitals, clinics, and consumers. It also exports its products to approximately 30 countries. The company was founded in 1979 and is headquartered in Cottonwood Heights, Utah. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/06 03:31
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.